roflumilast

FDA Drug Profile — ZORYVE, Roflumilast, Daliresp, ROFLUMILAST

roflumilast is listed in the FDA National Drug Code directory with 23 NDC codes, marketed under brand names including ZORYVE, Roflumilast, Daliresp. Available dosage forms: cream, tablet, aerosol, foam.

Drug details

Generic Name
roflumilast
Brand Names
ZORYVE, Roflumilast, Daliresp, ROFLUMILAST
Application Number
NDA215985
Sponsor
Arcutis Biotherapeutics, Inc.
NDC Codes
23
Dosage Forms
CREAM, TABLET, AEROSOL, FOAM
Routes
TOPICAL, ORAL
Active Ingredients
ROFLUMILAST

Indications and Usage

1 INDICATIONS AND USAGE Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use Roflumilast tablets are not a bronchodilator and are not indicated for the relief of acute bronchospasm. Roflumilast tablets 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose. Roflumilast is a selective phosphodiesterase 4 inhibitor indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. ( 1 , 14 ) Limitations of Use: Roflumilast tablets are not a bronchodilator and are not indicated for the relief of acute bronchospasm. ( 1 , 14 ) Roflumilast tablets 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose. ( 2 , 14 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.